In some of the first Elmiron cases that have been filed, the plaintiff's allege that Teva Branded Pharmaceutical Products R&D, Teva Pharmaceuticals USA, Inc., Janssen Pharmaceuticals, Inc, and Johnson & Johnson, Inc. manufactured and sold a dangerously defective prescription drug known as Elmiron (pentosyn polysulfate sodium).  The drug Elmiron was prescribed for the treatment of interstitial cystitis and bladder pain. Each of the Defendants designed, marketed, and distributed Elmiron in the United States, all the while knowing significant risks that were never disclosed to the medical and healthcare community, including Plaintiff’s prescribing doctor, Food and Drug Administration or the public in general. Further, all of the Defendants failed to provide adequate warnings to patients and the medical community, including Plaintiff’s prescribing physician, of the risks associated with using the drug. Throughout the time Defendants marketed Elmiron, all of the Defendants withheld material adverse events from the public, medical community and FDA. All of the Defendants failed to disclose the serious link between Elmiron use and significant visual damage, including pigmentary maculopathy and toxic maculopathy. Ultimately, tens of thousands of patients, were placed at risk and harmed as a result of this misleading conduct.

Have You Suffered From Vision Loss after Taking Elmiron?

YOU MAY BE ENTITLED TO COMPENSATION. COMPLETE THE FORM BELOW FOR A FREE CASE EVALUATION.

In some of the first Elmiron cases that have been filed, the plaintiff’s allege that Teva Branded Pharmaceutical Products R&D, Teva Pharmaceuticals USA, Inc., Janssen Pharmaceuticals, Inc, and Johnson & Johnson, Inc. manufactured and sold a dangerously defective prescription drug known as Elmiron (pentosyn polysulfate sodium).  The drug Elmiron was prescribed for the treatment of interstitial cystitis and bladder pain. Each of the Defendants designed, marketed, and distributed Elmiron in the United States, all the while knowing significant risks that were never disclosed to the medical and healthcare community, including Plaintiff’s prescribing doctor, Food and Drug Administration or the public in general. Further, all of the Defendants failed to provide adequate warnings to patients and the medical community, including Plaintiff’s prescribing physician, of the risks associated with using the drug. Throughout the time Defendants marketed Elmiron, all of the Defendants withheld material adverse events from the public, medical community and FDA. All of the Defendants failed to disclose the serious link between Elmiron use and significant visual damage, including pigmentary maculopathy and toxic maculopathy. Ultimately, tens of thousands of patients, were placed at risk and harmed as a result of this misleading conduct.

Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceuticals was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Until 2020, Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed by US-based Pfizer. Overall, Teva is the 18th largest pharmaceutical company in the world.

Teva’s facilities are located in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).